This tool is for research exploration only. It is not a medical device and does not provide medical advice. Drug candidates, evidence scores, and AI-generated content are not clinical recommendations. Always consult your medical team before making any treatment decisions.
Lutetium-177 DOTATATE
Lutathera
Peptide receptor radionuclide therapy (PRRT) / SSTR2-targeted radioligand therapy
Evidence Score
35
177Lu-DOTATATE (lutetium-177 oxodotreotide) is a radioligand comprising DOTA-Tyr3-octreotate (DOTATATE) — a somatostatin analogue with very high SSTR2 selectivity — conjugated to the β/γ-emitting radionuclide lutetium-177. In SSTR2-expressing tumors, DOTATATE binds SSTR2 at the cell surface, is internalized with the receptor, and delivers β-particle radiation (mean tissue range ~670 μm; maximum energy 497 keV) that causes dense, cytotoxic DNA double-strand breaks within the tumor cell and, via the crossfire effect, in adjacent SSTR2-negative cells. In SDH-deficient pheochromocytoma and paraganglioma (PCC/PGL), two mechanistic lines converge. First, SDH-deficient PPGL are confirmed SSTR2-high by functional DOTATATE-PET/CT imaging and IHC (PMID 42454478), conferring high peptide uptake and high absorbed radioligand dose per tumor cell. Second, SSTR2 is a direct pharmacological vulnerability in SDHB-deficient cells: the selective SSTR2 full agonist BIM-23120 significantly reduces proliferation and induces apoptosis in SDHB-deficient PCC/PGL cells versus wild-type counterparts (Ballard et al., Mol Biomed 2026, PMID 41928014) — an effect not reproduced by cold partial-agonist SSAs (octreotide, lanreotide). 177Lu-DOTATATE effectively provides full SSTR2 agonism (DOTATATE as high-affinity SSTR2 ligand) combined with targeted intratumoural radiotoxicity — a dual-mechanism attack aligned with the SSTR2 vulnerability established in vitro. An additional synergy is plausible: the BRCAness phenotype in all SDH-deficient cells (Mechanism 14 — succinate-mediated KDM4B inhibition → H3K9me3 persistence at DSB sites → HR deficiency; Sulkowski et al., Nat Genet 2018, PMID 30013182; Nature 2020, PMID 32494005) means SDH-deficient PPGL cells cannot efficiently resolve radiation-induced DSBs via homologous recombination — potentially conferring higher radiosensitivity to 177Lu-DOTATATE than matched SSTR2+ SDH-intact NETs. 177Lu-DOTATATE (Lutathera) is FDA-approved for SSTR2-positive, well-differentiated, progressive gastroenteropancreatic NETs (NETTER-1 Phase 3: Strosberg et al., NEJM 2017, PMID 28273561; NCT01578239); off-label PRRT for SSTR2-positive PCC/PGL is established practice at specialized radioligand therapy centers. Key limitations: (1) not formally FDA-approved for PPGL; off-label regulatory landscape varies by country; (2) requires SSTR2-positive disease (DOTATATE-PET/CT uptake) — most SDH-deficient PPGL qualify; (3) available only at accredited PRRT/radioligand therapy centres with nuclear medicine infrastructure; (4) the SSTR2 vulnerability applies to SDH-deficient PPGL (neuroendocrine lineage); SDH-deficient GIST (mesenchymal) and RCC do not typically express SSTR2 at therapeutic levels; (5) cumulative renal dose and bone marrow reserve must be monitored across treatment cycles.
Succinate accumulation competitively inhibits the α-KG-dependent histone demethylases KDM4A and KDM4B (JMJD2A/B), which normally erase repressive H3K9me3 marks at sites of DNA double-strand breaks. When KDM4B is inhibited, H3K9me3 hypermethylation persists at break sites, blocking recruitment of TIP60 acetyltransferase and ATM kinase — both required for DNA end-resection and initiation of homology-directed repair (HDR/HR). The result is a 'BRCAness' phenotype: SDH-deficient tumor cells have impaired HR capacity despite wild-type BRCA1/2. Sulkowski et al. (Nat Genet 2018, PMID: 30013182) directly demonstrated HR deficiency and olaparib hypersensitivity in cells and tumors from SDH-deficient hereditary paraganglioma/PPGL patients; Sulkowski et al. (Nature 2020, PMID: 32494005) dissected the KDM4B/H3K9me3 chromatin mechanism.
Upstream event:
SDH loss → succinate accumulation → competitive inhibition of KDM4A/KDM4B (α-KG-dependent H3K9me3 demethylases) → H3K9me3 persistence at DNA double-strand break sites → impaired TIP60/ATM recruitment → defective DNA end-resection → HR deficiency
Downstream effects:
SDH-deficient pheochromocytomas and paragangliomas (PCC/PGL) maintain high-level somatostatin receptor subtype 2 (SSTR2) expression. Full agonist activation of SSTR2 selectively suppresses proliferation and induces apoptosis in SDHB-deficient cells versus wild-type controls, identifying SSTR2 as a direct pharmacological vulnerability (Ballard et al., Mol Biomed 2026, PMID 41928014). Cold somatostatin analogues (partial agonists: octreotide, lanreotide) do not recapitulate the selective cytotoxicity — full receptor activation is required. The clinical corollary is that SSTR2 high expression in SDH-deficient PPGL confers eligibility for peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE, which simultaneously delivers full SSTR2 agonism and targeted β-radiation. The concurrent BRCAness phenotype (Mechanism 14) may synergize with PRRT-induced DSBs, since SDH-deficient cells have impaired HR capacity to resolve radiation damage. This mechanism is relevant to SDH-deficient PPGL (neuroendocrine lineage, SSTR2-high); SDH-deficient GIST and RCC are not typically SSTR2-expressing.
Upstream event:
SDH loss (SDHB mutation predominantly) → maintained neuroendocrine differentiation state with high SSTR2 expression; full SSTR2 agonism is selectively cytotoxic in SDHB-deficient versus SDH-intact PCC/PGL cells
Downstream effects:
SSTR2
Somatostatin receptor type 2
Gi-coupled G protein-coupled receptor for somatostatin and synthetic analogues. Highly expressed in SDH-deficient pheochromocytoma and paraganglioma; full agonist activation (BIM-23120) selectively suppresses proliferation and induces apoptosis in SDHB-deficient versus wild-type cells (PMID 41928014). High SSTR2 expression in SDH-deficient PPGL enables targeted peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE, which combines high-affinity SSTR2 binding with intratumoural β-radiation delivery. Partial agonists (cold SSAs: octreotide, lanreotide) bind SSTR2 but do not recapitulate the selective cytotoxicity observed with full agonism or PRRT. Target of Lutathera (177Lu-DOTATATE).
UniProt: P30874
Tumor Type Applicability
Approved Indications
- SSTR2-positive, well-differentiated, progressive, unresectable or metastatic gastroenteropancreatic neuroendocrine tumors (midgut NETs and pancreatic NETs)
Evidence from PubMed, OpenTargets, and ChEMBL will appear here once external data integration is enabled.
Coming in Phase 3
For research exploration only — not medical advice. Consult your doctor before acting on any information.
Have Claude analyze this drug's repurposing potential for SDH-deficient diseases.